Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Filings indexed 727 across all filing types
Latest filing 2026-05-16 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve the audited financial results ....
Regulatory Filings Classification · 85% confidence The document is an intimation to stock exchanges pursuant to SEBI listing regulations, notifying the date of the upcoming Board meeting and related compliance matters (trading window closure). It does not contain actual financial results or change of board personnel, nor is it a formal report itself. It is a regulatory announcement, fitting the fallback category “Regulatory Filings (RNS)”.
2026-05-16 English
Monitoring Agency Report
Regulatory Filings Classification · 80% confidence The document is a Monitoring Agency Report filed under SEBI (Listing Obligations & Disclosure Requirements) Regulation 32(6) detailing the utilisation of proceeds from a preferential issue of warrants. It contains tables of fund allocations and utilisation certified by CARE Ratings and is submitted as a continuous disclosure to the stock exchanges. This is a compliance document rather than a financial report or earnings announcement and does not fit into specific fundraising or capital-structure‐change notices. It therefore falls into the general “Regulatory Filings” category.
2026-05-15 English
Monitoring Agency Report for the quarter ended 31st March, 2026
Capital/Financing Update Classification · 75% confidence The document is a monitoring agency report submitted under SEBI LODR Regulation 32(6) detailing the utilization of proceeds from a Preferential Issue of convertible warrants for the quarter ended 31 March 2026. It is not an earnings release, interim or annual report, board/management change notice, or audit report; rather it provides ongoing compliance information on the use of financing proceeds. This falls squarely under “Capital/Financing Update” (CAP).
2026-05-15 English
Copy of Newspaper Publication
Regulatory Filings
2026-05-02 English
General Updates
Regulatory Filings
2026-04-30 English
Action(s) taken or orders passed
Regulatory Filings
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.